RecruitingPhase 1NCT06616623

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

A Phase Ib Study of Vismodegib and Atezolizumab in Patients With Advanced Non-Small Cell Lung Cancer (ML43922)

Sponsor

Dwight Owen

Enrollment

24 participants

Start Date

Dec 31, 2024

Study Type

INTERVENTIONAL

Conditions

Metastatic Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Recurrent Lung Non-Small Cell Carcinoma

Summary

This phase Ib trial tests the safety, side effects, and best dose of the combination of vismodegib and atezolizumab in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or has spread from where it first started (primary site) to other places in the body (metastatic). Vismodegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving a combination of vismodegib and atezolizumab may be safe, tolerable and/or effective than either drug alone in treating patients with recurrent or metastatic NSCLC.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of two drugs — vismodegib (which blocks a cancer growth pathway called Hedgehog signaling) and atezolizumab (an immunotherapy drug) — for people with non-small cell lung cancer (NSCLC) that has come back or spread and is no longer responding to standard treatment. **You may be eligible if...** - You are 18 or older - You have been confirmed to have recurrent or metastatic NSCLC with no curative options remaining - You have measurable cancer on scans - You have already received standard chemotherapy and/or immunotherapy - If your tumor has a known targetable mutation (like EGFR or ALK), you must have already tried all approved targeted therapies for it **You may NOT be eligible if...** - Your cancer has certain mutations that are still treatable with approved drugs you haven't tried yet - You have active autoimmune disease or recent severe immune-related side effects from prior immunotherapy - You have serious heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.